Transformative Fiscal 2026 Focused on Addressing Legacy Issues While Strengthening Foundation of the Company Beneficient Clears Litigation Hurdles as it Positions to Capitalize on New Opportunities for Growth DALLAS, June 29, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 fourth quarter and fiscal year, which ended March 31, 2026. Highlights of the year include:Resolved GWG Holdings, Inc. litigation and regained Nasdaq compliance Generated over $50 million in gross proceeds from asset sales Fully paid off HH-BDH Credit Agreement principal balance (excluding $1.1 million for deferred...

GREENWICH, Conn., June 29, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO) will hold its second quarter conference call and webcast on Thursday, July 30, at 8:30 a.m. Eastern Time. The company’s results will be released earlier that morning and made available on www.xpo.com. Access information:Call toll-free from US/Canada: 1-877-269-7756International callers: +1-201-689-7817Live webcast online at: www.xpo.com/investors A replay of the conference call will be available until August 29, 2026, by calling toll-free (from US/Canada) 1-877-660-6853; international callers dial +1-201-612-7415. Use the passcode 13761453. Additionally, the call will be archived on www.xpo.com/investors. About XPOXPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused...

Revenue and profit within guidance as reported A record-high second quarter $258M in cash flow from operations, $242M in adjusted free cash flow iX Suite deals up 400% year over yearNEWARK, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced financial results for the fiscal second quarter ended May 31, 2026.    Three Months Ended        May 31, 2026   May 31, 2025   ChangeRevenue($M)   $ 2,462.5     $ 2,417.4     1.9 %Operating income($M)   $ 95.4     $ 148.3     (35.7 )%Non-GAAP operating income($M) (1)   $ 292.0     $ 303.7     (3.9 )%Operating margin     3.9 %     6.1 %   -220 bpsNon-GAAP operating margin (1)     11.9 %     12.6 %   -70 bpsNet income($M)   $ 55.3     $ 42.1     31.4 %Non-GAAP net income($M) (1)   $ 168.6     $ 179.6     (6.1 )%Adjusted...

DSI Holding GmbH announces updated Consent Fee Record Date and payment date Munich, Germany, June 29, 2026 (GLOBE NEWSWIRE) — Reference is made to the notice of written procedure dated 12 June 2026 in respect of DSI Holding GmbH’s outstanding up to EUR 150,000,000 Senior Secured Callable Floating Rate Bonds 2025/2029 (ISIN: SE0025937956) (the “WP Notice”). DYWIDAG hereby announces that, due to administrative settlement considerations, the Consent Fee Record Date (as defined in the WP Notice) will fall on 30 June 2026. Subject to the approval of the Request (as defined in the WP Notice), the consent fee will be paid through Euroclear Sweden on 7 July 2026. The last day for voting in the written procedure is 2 July 2026. Contact information relating to the written procedure For questions to the Issuer regarding the Request, please...

ST. LOUIS, June 29, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 year ended March 31, 2026. FY2026 Financial Key Items (all comparisons to the prior year)Operating income from continuing operations of $1,010,017 compared to $730,005 in the prior year, an increase of over 38%   Net income was $656,420 or $0.10 per share compared to $465,599 or $0.06 per share in the prior year Revenues from operations were $18,933,531 compared to $21,373,673 in the prior fiscal year Subsequent to the end of the quarter, on May 15, 2026, the Company announced it had sold to an unaffiliated purchaser substantially all of the equipment assets of its construction business, Empire Construction, Inc., and all of the real property associated with the...

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update. The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July. “The FDA’s acceptance of our RP1 BLA resubmission marks a pivotal milestone in our mission...

Roadzen Posts First ‘Rule of 40’ Quarter in Two Years; FY2026 Net Loss Narrows 69% and Adjusted EBITDA Loss Improves 58%, with Seventh Straight Quarter of Adjusted EBITDA Gains Nearing BreakevenRecord Revenue Growth Drives Strongest Quarter in Company HistoryRoadzen delivered record fourth-quarter revenue of $16.1 million, up 42% year-over-year and 12% sequentially — the highest quarterly revenue in Company history. Full-year FY2026 revenue rose to a record $55.0 million, up 24% from $44.3 million in FY2025, reflecting sustained multi-quarter acceleration driven by rising customer adoption and expanding enterprise penetration. Net Loss Narrows Sharply; Adjusted EBITDA1 Approaches Break-EvenNet loss attributable to ordinary shareholders for FY2026 fell approximately 69% to $(22.5) million, or $(0.29) per share, from $(72.9) million, or...

– Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 – – Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”) has surpassed 88% enrollment and is on track for topline data readout in Q4 20262,3 – – HLP003 Phase 2 data demonstrated durability at 12 months following two 16mg doses, with 100% response and 71% remission based on a MADRS benchmark of ≤10, with remission rising to 100% based on recent peer benchmarks of ≤124,5 – – Reported topline results in Phase 2 signal detection study for HLP004 in Generalized Anxiety Disorder (“GAD”) showing ~10-point improvement from baseline in...

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated. “Fiscal year 2026 marked a significant transition for Appili as we advanced commercial-stage programs and continued to build our non-dilutive funding base,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics. “With...

First Half Fiscal Year 2026 Revenue up 7.7% to $17.7 Million Period over Period Accelerating Enterprise AI Adoption Fuels Market Expansion, Unlocking New Opportunities in AI-Powered Customer Engagement SAN DIEGO and SINGAPORE, June 26, 2026 (GLOBE NEWSWIRE) — Helport AI Limited (NASDAQ: HPAI) (“Helport AI” or the “Company”), a global artificial intelligence (“AI”) workforce infrastructure company providing intelligent communication software and services to enterprise clients, today announced its unaudited financial results for the six months ended December 31, 2025. First Half Fiscal Year 2026 Highlights  Average monthly subscribed users of AI Assist services were 37,908 for the six months ended December 31, 2025, representing an increase of 16.8% from 32,468 in the same period of 2024.Revenue for the six months ended December...